Tags : (lanadelumab)

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study

Vartika Singh June 4, 2019

Shots: The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg, SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 […]readmore

Pharma

Shire’s Takhzyro IV (lanadelumab) Receives EU’s Approval for Hereditary Angioedema

Vartika Singh December 3, 2018

Shots: The approval is based on P-III HELP study results assessing Takhzyro (300 mg q2w, 300 mg q4w, 150 mg q4w) vs PBO in 125 patients with HAE aged ≥12 […]readmore

Tags : (lanadelumab)

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study

Shire’s Takhzyro IV (lanadelumab) Receives EU’s Approval for Hereditary Angioedema

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : (lanadelumab)

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study

Shire’s Takhzyro IV (lanadelumab) Receives EU’s Approval for Hereditary Angioedema

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company